Sponsored Content by MerckReviewed by Louis CastelOct 9 2026
The rapid evolution of nanomedicine has elevated drug delivery from a formulation challenge to a critical factor determining therapeutic success. Whether developing mRNA vaccines, cancer therapeutics, or targeted gene therapies, researchers must balance particle size, encapsulation efficiency, and reproducibility, all while accelerating development timelines.
Microfluidic technologies are emerging as a powerful solution to these challenges. By enabling precise control over nanoparticle formation, they offer researchers a faster and more reproducible alternative to conventional formulation methods. Combined with ready-to-use formulation kits, these platforms are making sophisticated nanoparticle development more accessible for laboratories across academia and industry.
Image Credit: CI Photos/Shutterstock.com
Why formulation matters in modern drug delivery
The effectiveness of many modern therapeutics depends not only on the active pharmaceutical ingredient but also on the carrier that transports it. Lipid nanoparticles, polymeric nanoparticles, microparticles, and liposomes protect sensitive molecules, improve stability, enhance bioavailability, and enable targeted delivery.
This has become especially important for nucleic acid therapeutics such as mRNA, siRNA, and DNA, where successful delivery directly influences therapeutic performance. The widespread adoption of lipid nanoparticles in mRNA vaccines has further demonstrated the importance of robust formulation technologies.
The limitations of conventional nanoparticle production
Traditional nanoparticle fabrication methods, including nanoprecipitation and extrusion, have supported pharmaceutical research for many years. However, these approaches often require extensive optimization to achieve the desired particle size and loading efficiency.
Researchers may encounter:
- Batch-to-batch variability
- Broad particle size distributions
- Time-consuming optimization workflows
- Significant reagent consumption
- Challenges when scaling formulations for larger studies
These issues can slow development and make it difficult to reproduce promising formulations across different laboratories.
How microfluidics improves drug delivery formulation
Microfluidic devices address many of these limitations by precisely controlling how fluids mix within microscale channels.
Unlike conventional bulk mixing, microfluidic systems exploit highly controlled laminar flow, allowing nanoparticles to assemble under tightly regulated conditions. This results in more uniform particle formation with narrower size distributions and improved reproducibility.
Researchers can also adjust flow conditions to fine-tune particle characteristics for specific applications while using significantly smaller reagent volumes. These advantages make microfluidics particularly attractive for early-stage formulation screening and process development.
A complete workflow for nanoparticle development
Recent advances have combined microfluidic hardware with pre-optimized reagent kits to simplify formulation development even further.
The NanoFabTx™ platform, for example, integrates formulation screening kits with plug-and-play microfluidic device kits that can be connected directly to standard syringe pumps or compatible pressure-driven systems. Rather than assembling formulations from individual components, researchers receive carefully selected polymer or lipid formulations together with validated protocols.
This integrated approach reduces trial-and-error optimization while enabling reproducible synthesis of lipid nanoparticles, liposomes, polymeric nanoparticles, and microparticles suitable for a broad range of research applications.
Supporting diverse drug delivery strategies
Modern drug delivery extends well beyond traditional small molecule therapeutics. Current formulation strategies support applications including:
- mRNA vaccines
- Gene delivery
- Small molecule therapeutics
- Protein and peptide delivery
- Oncology and immuno-oncology research
- Precision medicine
Depending on the selected formulation chemistry, researchers can prepare biodegradable polymer nanoparticles based on materials such as PLA, PLGA, and PCL, or generate lipid nanoparticles using specialized lipid mixtures designed for nucleic acid delivery. PEGylated, cationic, and functionalized lipid formulations further expand the design possibilities for targeted delivery applications.
Greater control over particle characteristics
One of the most significant advantages of combining formulation kits with microfluidics is the ability to consistently produce particles with defined characteristics.
Researchers can optimize:
- Particle size
- Size distribution
- Drug loading capacity
- Encapsulation efficiency
- Particle morphology
The NanoFabTx™ microfluidic platform is designed to produce nanoparticles and liposomes in the 100 to 200 nm range with narrow size dispersity, while complementary microfluidic systems support the synthesis of larger microparticles for extended delivery applications.
Accelerating mRNA vaccine development
The rapid development of mRNA vaccines highlighted the importance of scalable, reproducible lipid nanoparticle production.
Microfluidic synthesis enables highly controlled mixing of lipids and nucleic acids, producing consistent lipid nanoparticles that are critical for vaccine quality and performance. Beyond vaccine development, the same principles are now being applied to a wide range of RNA therapeutics entering clinical development.
As demand for nucleic acid medicines continues to grow, microfluidic manufacturing is expected to play an increasingly important role in research.
Simplifying formulation development
One of the greatest barriers to nanoparticle research has traditionally been the expertise required to develop stable formulations.
By combining validated reagent kits with detailed protocols and modular microfluidic devices, researchers can focus more on therapeutic design and biological evaluation rather than lengthy formulation optimization.
This streamlined workflow reduces material waste, shortens development timelines, and improves reproducibility between experiments, making advanced drug delivery research more accessible to laboratories with varying levels of formulation experience. However, these formulations and protocols should be viewed as validated starting points developed using model APIs, rather than universal solutions. API-specific optimization, including lipid or polymer ratios, flow rates, and buffer exchange conditions, will still be required for each new compound.
Looking ahead
As biologics, gene therapies, and RNA medicines continue to expand, drug delivery technologies will become even more central to pharmaceutical innovation.
Microfluidics offers a practical pathway toward reproducible nanoparticle synthesis, precise control over formulation parameters, and a foundation for future scale-up efforts, which require dedicated process development and validation at each scale. When combined with ready-to-use formulation platforms, these technologies are helping researchers accelerate development while improving consistency from early discovery through translational research.
With continued advances in microfluidic engineering and formulation science, the next generation of drug delivery systems is poised to become more efficient, reproducible, and adaptable than ever before.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.